Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials | Cerebrovascular Disease | JAMA Neurology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.39.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Wang  Y, Wang  Y, Zhao  X,  et al; CHANCE Investigators.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.  N Engl J Med. 2013;369(1):11-19. doi:10.1056/NEJMoa1215340PubMedGoogle ScholarCrossref
2.
Johnston  SC, Easton  JD, Farrant  M,  et al; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators.  Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.  N Engl J Med. 2018;379(3):215-225. doi:10.1056/NEJMoa1800410PubMedGoogle ScholarCrossref
3.
Grotta  JC.  Antiplatelet therapy after ischemic stroke or TIA.  N Engl J Med. 2018;379(3):291-292. doi:10.1056/NEJMe1806043PubMedGoogle ScholarCrossref
4.
GUSTO investigators.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.  N Engl J Med. 1993;329(10):673-682. doi:10.1056/NEJM199309023291001PubMedGoogle ScholarCrossref
5.
Hao  Q, Tampi  M, O’Donnell  M, Foroutan  F, Siemieniuk  RA, Guyatt  G.  Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.  BMJ. 2018;363:k5108. doi:10.1136/bmj.k5108PubMedGoogle ScholarCrossref
6.
Pan  Y, Jing  J, Chen  W,  et al; CHANCE investigators.  Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.  Neurology. 2017;88(20):1906-1911. doi:10.1212/WNL.0000000000003941PubMedGoogle ScholarCrossref
7.
Kim  JT, Park  MS, Choi  KH,  et al.  Comparative effectiveness of aspirin and clopidogrel versus aspirin in acute minor stroke or transient ischemic attack.  Stroke. 2018;50(1):A118022691.PubMedGoogle Scholar
8.
Kennedy  J, Hill  MD, Ryckborst  KJ, Eliasziw  M, Demchuk  AM, Buchan  AM; FASTER Investigators.  Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.  Lancet Neurol. 2007;6(11):961-969. doi:10.1016/S1474-4422(07)70250-8PubMedGoogle ScholarCrossref
9.
Wang  Y, Liu  M, Pu  C.  2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack.  Int J Stroke. 2017;12(3):302-320. doi:10.1177/1747493017694391PubMedGoogle ScholarCrossref
10.
Powers  WJ, Rabinstein  AA, Ackerson  T,  et al; American Heart Association Stroke Council.  2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.  Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158PubMedGoogle ScholarCrossref
11.
Boulanger  JM, Lindsay  MP, Gubitz  G,  et al.  Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th Edition, update 2018.  Int J Stroke. 2018;13(9):949-984. doi:10.1177/1747493018786616PubMedGoogle ScholarCrossref
12.
Stroke Foundation. Clinical guidelines for stroke management 2017. https://informme.org.au/en/Guidelines/Clinical-Guidelines-for-Stroke-Management-2017. Published 2017. Accessed July 12, 2019.
13.
Royal College of Physicians. National clinical guideline for stroke: prepared by the Intercollegiate Stroke Working Party, 5th edition. https://www.strokeaudit.org/SupportFiles/Documents/Guidelines/2016-National-Clinical-Guideline-for-Stroke-5t-(1).aspx. Published 2016. Accessed July 12, 2019.
14.
Prasad  K, Siemieniuk  R, Hao  Q,  et al.  Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.  BMJ. 2018;363:k5130. doi:10.1136/bmj.k5130PubMedGoogle ScholarCrossref
15.
Ferreiro  JL, Sibbing  D, Angiolillo  DJ.  Platelet function testing and risk of bleeding complications.  Thromb Haemost. 2010;103(6):1128-1135. doi:10.1160/TH09-11-0799PubMedGoogle ScholarCrossref
16.
Rahman  H, Khan  SU, Nasir  F, Hammad  T, Meyer  MA, Kaluski  E.  Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack.  Stroke. 2019;50(4):947-953. doi:10.1161/STROKEAHA.118.023978PubMedGoogle ScholarCrossref
17.
Yang  Y, Zhou  M, Zhong  X,  et al.  Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis.  Stroke Vasc Neurol. 2018;3(2):107-116. doi:10.1136/svn-2018-000168PubMedGoogle ScholarCrossref
18.
Ding  L, Peng  B.  Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.  Eur J Neurol. 2018;25(10):1276-1284. doi:10.1111/ene.13695PubMedGoogle ScholarCrossref
19.
Stewart  LA, Parmar  MK.  Meta-analysis of the literature or of individual patient data: is there a difference?  Lancet. 1993;341(8842):418-422. doi:10.1016/0140-6736(93)93004-KPubMedGoogle ScholarCrossref
20.
Benavente  OR, Hart  RG, McClure  LA, Szychowski  JM, Coffey  CS, Pearce  LA; SPS3 Investigators.  Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.  N Engl J Med. 2012;367(9):817-825. doi:10.1056/NEJMoa1204133PubMedGoogle ScholarCrossref
21.
Jing  J, Meng  X, Zhao  X,  et al.  Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial.  JAMA Neurol. 2018;75(6):711-719. doi:10.1001/jamaneurol.2018.0247PubMedGoogle ScholarCrossref
Original Investigation
August 19, 2019

Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials

Author Affiliations
  • 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
  • 2China National Clinical Research Center for Neurological Diseases, Beijing, China
  • 3Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
  • 4Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
  • 5Department of Public Health Sciences, Medical University of South Carolina, Charleston
  • 6Department of Neurology, University of California, San Francisco
  • 7Department of Emergency Medicine, University of Michigan, Ann Arbor
  • 8Department of Neurology, University of Michigan, Ann Arbor
  • 9Benefis Health System, Great Falls, Montana
  • 10Dean’s Office, Dell Medical School, University of Texas at Austin
JAMA Neurol. 2019;76(12):1466-1473. doi:10.1001/jamaneurol.2019.2531
Key Points

Question  What is the optimal duration of dual antiplatelet therapy for minor ischemic stroke or transient ischemic attack?

Findings  In this pooled analysis of 2 randomized clinical trials, early and short-term clopidogrel-aspirin treatment was associated with a reduction in the risk of major ischemic events without increasing the risk of major hemorrhage in patients with minor stroke or transient ischemic attack. The main net clinical benefit of dual antiplatelet therapy occurred within the first 21 days.

Meaning  This analysis suggests that, in patients with acute minor stroke or transient ischemic attack, dual antiplatelet therapy should be initiated as soon as possible, but preferably within 24 hours after symptom onset, and continued for a duration of 21 days.

Abstract

Importance  Dual antiplatelet therapy with clopidogrel and aspirin is effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA). Uncertainties remained about the optimal duration of dual antiplatelet therapy for minor stroke or TIA.

Objective  To obtain precise estimates of efficacy and risk of dual antiplatelet therapy after minor ischemic stroke or TIA.

Design, Setting, and Participants  This analysis pooled individual patient–level data from 2 large-scale randomized clinical trials that evaluated clopidogrel-aspirin as a treatment to prevent stroke after a minor stroke or high-risk TIA. The Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) trial enrolled patients at 114 sites in China from October 1, 2009, to July 30, 2012. The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial enrolled patients at 269 international sites from May 28, 2010, to December 19, 2017. Both were followed up for 90 days. Data analysis occurred from November 2018 to May 2019.

Interventions  In the 2 trials, patients with minor stroke or high-risk TIA were randomized to clopidogrel-aspirin or aspirin alone within 12 hours (POINT) or 24 hours (CHANCE) of symptom onset.

Main Outcomes and Measures  The primary efficacy outcome was a major ischemic event (ischemic stroke, myocardial infarction, or death from ischemic vascular causes). The primary safety outcome was major hemorrhage.

Results  The study enrolled 5170 patients (CHANCE) and 4881 patients (POINT). Analysis included individual data from 10 051 patients (5016 in the clopidogrel-aspirin treatment group and 5035 in the control group) with a median age of 63.2 (interquartile range, 55.0-72.9) years; 6106 patients (60.8%) were male. Clopidogrel-aspirin treatment reduced the risk of major ischemic events at 90 days compared with aspirin alone (328 of 5016 [6.5%] vs 458 of 5035 [9.1%]; hazard ratio [HR], 0.70 [95% CI, 0.61-0.81]; P < .001), mainly within the first 21 days (263 of 5016 [5.2%] vs 391 of 5035 [7.8%]; HR, 0.66 [95% CI, 0.56-0.77]; P < .001), but not from day 22 to day 90. No evidence of heterogeneity of treatment outcome across trials or prespecified subgroups was observed. Major hemorrhages were more frequent in the clopidogrel-aspirin group, but the difference was nonsignificant.

Conclusions and Relevance  In this analysis of the POINT and CHANCE trials, the benefit of dual antiplatelet therapy appeared to be confined to the first 21 days after minor ischemic stroke or high-risk TIA.

×